Strongbridge Biopharma plc.
SBBP
SBBP was delisted on the 5th of October, 2021.
0 hedge funds and large institutions have $0 invested in Strongbridge Biopharma plc. in 2021 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 49 closing their positions.
100% less funds holding
Funds holding: 49 → 0 (-49)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
100% less capital invested
Capital invested by funds: $69.8M → $0 (-$69.8M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 49
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Caxton Corporation
Princeton,
New Jersey
|
-$16.4M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$9.16M |
| 3 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$8.45M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$6.27M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.49M |
SBBP Hedge Fund Activity: Q4 2021 in Review
0 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Strongbridge Biopharma plc. (SBBP) for Q4 2021, worth a combined $0 — down 100% from $69.8M a quarter earlier.
Sellers outnumbered buyers: 49 funds closed out of SBBP and 0 opened new positions — a net loss of 49 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Caxton Corporation, exiting entirely with an estimated $16.4M sold.
- 0 institutional investors held Strongbridge Biopharma plc. (SBBP) as of Q4 2021, down from 49 in Q3 2021.
- Funds reported $0 of Strongbridge Biopharma plc. stock for Q4 2021, down 100% quarter-over-quarter.
- 0 funds opened new Strongbridge Biopharma plc. positions in Q4 2021 and 49 closed out, a net change of -49 holders.
- The largest Strongbridge Biopharma plc. seller in Q4 2021 was Caxton Corporation, an estimated $16.4M sold.
Based on aggregated 13F filings for Q4 2021.